Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Hong Kong ETF (EWH) vs Novavax Inc (NVAX) Price & Performance

iShares MSCI Hong Kong ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Hong Kong ETF vs Novavax Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.05, while Novavax Inc trades at $8.49 (market cap $1.39B). Which is the better fit depends on your goals.

EWHNVAX
Sector
Broad Market / FactorHealth
52-Week High
$24.55$11.19
52-Week Low
$20.15$6.22
Market Cap
$1.39B
Enterprise Value
$890.94M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Hong Kong ETF

EWH, the iShares MSCI Hong Kong ETF, trades at $22.04, up 1.71% with a bullish technical signal from moving averages. The ETF tracks Hong Kong equities, showing recent momentum in Chinese technology stocks as highlighted in recent market coverage. Key resistance and support cluster around $22, while RSI readings suggest potential overbought conditions. The fund declared a $0.35 dividend payable in June 2026.

Outlook remains tied to Hong Kong market performance and Chinese economic factors. Positive catalysts include technology sector rallies and Hong Kong's growing wealth hub status, but risks involve regulatory scrutiny on Chinese brokerages and IPO performance concerns. Investor sentiment is cautiously optimistic amid regional market volatility.

Novavax Inc

Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.

The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Hong Kong ETF

EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.

Read more on EWH

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX